June 10 (Reuters) - Clovis Oncology Inc:
* CLOVIS ONCOLOGY ANNOUNCES COMPLETION OF TARGET ENROLLMENT IN THE ATHENA TRIAL, A PHASE 3 MAINTENANCE TREATMENT STUDY IN FRONT-LINE, NEWLY-DIAGNOSED ADVANCED OVARIAN CANCER
* CLOVIS ONCOLOGY INC - TOPLINE DATA FOR RUBRACA MONOTHERAPY ARM VERSUS PLACEBO EXPECTED 2H 2021
* CLOVIS ONCOLOGY - TOPLINE DATA FROM RUBRACA & OPDIVO IN COMBINATION VERSUS RUBRACA MONOTHERAPY EXPECTED ONE YEAR OR MORE LATER Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.